<DOC>
	<DOCNO>NCT02115373</DOCNO>
	<brief_summary>This Phase 1b/2 , multicenter , single arm trial ass efficacy , safety , pharmacokinetics ( PK ) MSC2156119J monotherapy subject MET+ advance hepatocellular carcinoma ( HCC ) child Pugh Class A liver function fail sorafenib treatment .</brief_summary>
	<brief_title>c-Met Second-Line Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Histologically confirm HCC Child Pugh Class A liver function score For Phase 2 : MET+ status Male female , 18 year age old Measurable disease accordance Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 ( inclusive ) Availability pretreatment tumor biopsy ( exclude fine needle aspiration cytology sample ) take subject discontinue sorafenib within 28 day day first dose MSC2156119J . From pretreatment biopsy either formalinfixed ( formalin fixation mandatory ) paraffinembedded block tumor tissue ( prefer ) least 15 unstained slide must send central laboratory prior enrollment . An associated pathology report must also send sample Previously treat sorafenib great equal 4 week discontinue sorafenib treatment least 14 day prior Day 1 due either intolerance radiographic progression Signed date informed consent indicate subject ( legally acceptable representative applicable local law ) inform pertinent aspect trial prior enrollment Willingness ability comply schedule visit , treatment plan , laboratory test trial procedure Life expectancy least 3 month judge investigator Prior systemic anticancer treatment advance HCC ( except sorafenib describe inclusion criterion ) Prior treatment agent target hepatocyte growth factor ( HGF ) /cMet pathway Localregional therapy within 4 week Day 1 Impaired cardiac function Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>c-Met inhibitor</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>MSC2156119J</keyword>
</DOC>